000			03296nam a22003855i 4500
001			100406
003			DE-He213
005			20230102112954.0
007			cr nn 008mamaa
008			171031s2018 gw | s |||| 0|eng d
020			_a9783319618722 _9
024	7		_a10.1007/978-3-319-61872-2 _2doi
040			_aES-MaUEC _bspa
050		4	_aRC280.B6 2018 EB
245	1	0	_aPersonalized Therapy for Multiple Myeloma _cedited by Saad Z. Usmani, Ajay K. Nooka.
264		1	_aCham _bSpringer International Publishing _c2018
300			_a1 recurso en línea (IX, 178 páginas 5 ilustraciones, 3 ilustraciones a color)
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
505	0		_aRisk stratification in newly diagnosed smoldering multiple myeloma -- Risk stratification in newly diagnosed transplant eligible multiple myeloma -- Risk stratification in newly diagnosed transplant ineligible multiple myeloma -- Treatment of translocation 4;14 and deletion 17 p MM -- Treatment of patients in first/second relapse -- Treatment of patients in third relapse and beyond including double refractory disease -- Treatment of primary and secondary plasma cell leukemia -- Practical considerations for bone health in multiple myeloma -- Personalizing MM treatment: gaps in knowledge that we need to overcome.
520	3		_aThis book provides the clinician with concise, practical guidance on risk stratification and therapeutic decision making in patients with multiple myeloma. In addition, the available clinical trial and research data are summarized into meaningful reviews and evidence-based recommendations for treatment are presented. The coverage encompasses all phases and forms of disease, including high-risk myeloma. Over recent decades, greater understanding of the biology of myeloma has fostered the development of new, more effective drugs, leading to remarkable improvements in survival. To continue this momentum, several recent prospective trials have aimed to identify further potential therapeutic targets or to evaluate various combinations of anti-myeloma agents. The increasing abundance of management options makes treatment decision making in different phases of disease. This book will offer the clinician valuable assistance in the choice and sequencing of therapies, highlighting the need for a personalized approach that reflects the growing recognition that myeloma is not one uniform disease.
650		7	_aOncología _2embne _9139207
650		7	_aMieloma múltiple _2embne _9160182
700	1		_aUsmani, Saad Z. _eeditor literario
700	1		_aNooka, Ajay K. _eeditor literario _0http://id.loc.gov/authorities/names/n2018183930 _0http://viaf.org/viaf/17152682496223311016
776	0	8	_iEdición impresa: _z9783319618715
776	0	8	_iEdición impresa: _z9783319618739
776	0	8	_iEdición impresa: _z9783319871820
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-61872-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
490	0		_aMedicine (Springer-11650)
988			_aSpringer_Medicine_2018
998			_b01/2019 _dz _ea _feng _ggw _h0
999			_c100406 _d100406 _x1